Marika Tardella
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marika Tardella has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Marco Di Carlo
Università Politecnica delle Marche, “Carlo Urbani” Hospital
7 shared publications - Fausto Salaffi
Università Politecnica delle Marche, “Carlo Urbani” Hospital
6 shared publications - Andrea Giovagnoni
Department of Clinical, Special and Dental Sciences, University Politecnica delle Marche, Ancona, Italy
4 shared publications - Marina Carotti
Department of Radiology, Ospedali Riuniti, Università Politecnica delle Marche, 60126 Ancona, Italy
4 shared publications - Alessandra Borgheresi
Department of Clinical, Special and Dental Sciences, University Politecnica delle Marche, Ancona, Italy
1 shared publication - Andrea Agostini
Department of Clinical, Special and Dental Sciences, University Politecnica delle Marche, Ancona, Italy
1 shared publication
Latest Publications
- 28 July 2025
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 21 (8) , 1019-1033
Evaluating the role of lung ultrasound in the diagnosis of rheumatoid arthritis-interstitial lung disease
The involvement of the pulmonary parenchyma in rheumatoid arthritis (RA), characterized by the presence of interstitial lung disease (RA-ILD), represents one of the most common and potentially severe extra-articular manifestations of the disease. High-resolution computed tomography (HRCT) of the chest is considered the gold standard diagnostic technique; however, its reliance on ionizing radiation and the limited availability of imaging equipment make it challenging to perform repeatedly. Over the past decade, lung ultrasound (LUS) has emerged as a noninvasive and easily repeatable technique for detecting the presence of RA-ILD. This narrative review summarizes the currently available evidence on the use of LUS in RA-ILD. It begins by defining the elementary lesions indicative of pulmonary involvement (B-lines and pleural irregularities) and provides an overview of LUS application in other connective tissue disease-associated interstitial lung diseases (CTD-ILDs). Current evidence suggests a promising role for LUS in the screening of RA-ILD, primarily based on the quantification of B-lines. Initially, a threshold of 10 B-lines was proposed, which has recently been lowered to 5, demonstrating good sensitivity and specificity in detecting RA-ILD. Future directions should focus on the role of pleural irregularities and the further standardization of the technique.
- 28 July 2025
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 21 (8) , 1019-1033
Evaluating the role of lung ultrasound in the diagnosis of rheumatoid arthritis-interstitial lung disease
The involvement of the pulmonary parenchyma in rheumatoid arthritis (RA), characterized by the presence of interstitial lung disease (RA-ILD), represents one of the most common and potentially severe extra-articular manifestations of the disease. High-resolution computed tomography (HRCT) of the chest is considered the gold standard diagnostic technique; however, its reliance on ionizing radiation and the limited availability of imaging equipment make it challenging to perform repeatedly. Over the past decade, lung ultrasound (LUS) has emerged as a noninvasive and easily repeatable technique for detecting the presence of RA-ILD. This narrative review summarizes the currently available evidence on the use of LUS in RA-ILD. It begins by defining the elementary lesions indicative of pulmonary involvement (B-lines and pleural irregularities) and provides an overview of LUS application in other connective tissue disease-associated interstitial lung diseases (CTD-ILDs). Current evidence suggests a promising role for LUS in the screening of RA-ILD, primarily based on the quantification of B-lines. Initially, a threshold of 10 B-lines was proposed, which has recently been lowered to 5, demonstrating good sensitivity and specificity in detecting RA-ILD. Future directions should focus on the role of pleural irregularities and the further standardization of the technique.
- Open Access
- 24 April 2022
- Published by Springer Nature in Inflammopharmacology
- Vol. 30 (3) , 705-712
A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease
Objectives: To examine the effectiveness of Janus-kinase inhibitors (JAKis) or abatacept (ABA) in patients with rheumatoid arthritis-interstitial lung disease (RA-ILD). Methods: Patients with RA-ILD receiving JAKis or ABA were retrospectively evaluated at baseline and after 18 months of treatment. A computer-aided method (CaM) was used to assess the extent of high-resolution computed tomography (HRCT) fibrosis percentage. According to HRCT fibrosis changes, patients were classified as “worsened” (progression of 15% or more), “stable” (changes within 15%) or “improved” (reduction of 15% or more). Correlations between RA characteristics and JAKis or ABA responses were studied using a multivariate regression model. Results: Seventy-five patients (69.3% women) were evaluated, 31 received a JAKi while 44 received ABA. In the JAKis group, five patients (16.1%) showed RA-ILD progression, 20 patients (64.5%) were considered stable, and six patients (19.4%) demonstrated RA-ILD improvement. In the ABA group, five patients (11.3%) showed RA-ILD progression, 32 patients (72.7%) were stable, and seven patients (16.0%) demonstrated RA-ILD improvement. In both groups, the percentage of current smokers was different between those classified as "worsened" and those classified as "improved/stable" (p = 0.01). In multivariate regression analysis, current smoking habit (p = 0.0051) and concomitant methotrexate treatment (p = 0.0078) were the two variables related to RA-ILD progression in ABA-treated patients, whereas in JAKis-treated patients, the only RA-ILD progression-related variable was disease duration of RA (p < 0.001). Conclusions: Treatment with JAKis or ABA was related to stability or improvement of RA-ILD in 83.9% and 88.6% of patients, respectively. RA duration is the only variable associated with worsening RA-ILD in JAKis-treated patients.
- 24 April 2022
- Published by Springer Nature in Inflammopharmacology
- Vol. 30 (3) , 705-712
Open AccessA retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease
Objectives: To examine the effectiveness of Janus-kinase inhibitors (JAKis) or abatacept (ABA) in patients with rheumatoid arthritis-interstitial lung disease (RA-ILD). Methods: Patients with RA-ILD receiving JAKis or ABA were retrospectively evaluated at baseline and after 18 months of treatment. A computer-aided method (CaM) was used to assess the extent of high-resolution computed tomography (HRCT) fibrosis percentage. According to HRCT fibrosis changes, patients were classified as “worsened” (progression of 15% or more), “stable” (changes within 15%) or “improved” (reduction of 15% or more). Correlations between RA characteristics and JAKis or ABA responses were studied using a multivariate regression model. Results: Seventy-five patients (69.3% women) were evaluated, 31 received a JAKi while 44 received ABA. In the JAKis group, five patients (16.1%) showed RA-ILD progression, 20 patients (64.5%) were considered stable, and six patients (19.4%) demonstrated RA-ILD improvement. In the ABA group, five patients (11.3%) showed RA-ILD progression, 32 patients (72.7%) were stable, and seven patients (16.0%) demonstrated RA-ILD improvement. In both groups, the percentage of current smokers was different between those classified as "worsened" and those classified as "improved/stable" (p = 0.01). In multivariate regression analysis, current smoking habit (p = 0.0051) and concomitant methotrexate treatment (p = 0.0078) were the two variables related to RA-ILD progression in ABA-treated patients, whereas in JAKis-treated patients, the only RA-ILD progression-related variable was disease duration of RA (p < 0.001). Conclusions: Treatment with JAKis or ABA was related to stability or improvement of RA-ILD in 83.9% and 88.6% of patients, respectively. RA duration is the only variable associated with worsening RA-ILD in JAKis-treated patients.
- Open Access
- 27 July 2021
- Published by Springer Nature in Clinical Rheumatology
- Vol. 40 (12) , 4861-4867
Abatacept in rheumatoid arthritis-associated interstitial lung disease: short-term outcomes and predictors of progression
Introduction: Interstitial lung disease in rheumatoid arthritis (RA-ILD) is an extra-articular involvement that impairs the prognosis and for which there is still no well-coded treatment. The aim of this study was to evaluate abatacept (ABA) effectiveness and safety in patients with RA-ILD. Methods: RA-ILD patients who started ABA treatment were consecutively enrolled. Chest high-resolution computed tomography (HRCT), clinical, laboratory and respiratory function variables were collected at baseline and after 18 months of ABA treatment. HRCT abnormalities were evaluated using a computer-aided method (CaM). ABA response was established based on the change in the percentage of fibrosis evaluated at HRCT-CaM, dividing patients into “worsened” (progression ≥ 15%), “improved” (reduction ≥ 15%), and “stable” (changes within the 15% range). The multivariate regression model was used to assess the associations between RA characteristics and ABA response. Results: Forty-four patients (81% women, mean age 59.1 ± 8.0, mean disease duration of 7.5 ± 3.1 years) were studied. Five patients (11.4%) showed RA-ILD progression, 32 patients (72.6%) were considered stable, and 7 patients (16.0%) showed an RA-ILD improvement. The proportion of current smokers was significantly different between “worsened” patients, respect to those defined as "improved/stable” (p = 0.01). Current smoking habit (p = 0.005) and concomitant methotrexate treatment (p = 0.0078) were the two variables related to RA-ILD progression in multivariate regression analysis. Conclusion: Treatment with ABA is associated with a RA-ILD stability or improvement in the 88.6% of patients. Current smoking habit and concomitant treatment with methotrexate are the modifiable factors associated with RA-ILD worsening. Key Points• Abatacept plays a favourable role in the control of RA-ILD, with a significant worsening in only 11.4% of patients during a 18-month follow-up period.• The predictive variables related to RA-ILD progression during abatacept therapy are the concomitant treatment with methotrexate and current smoking habit.
- 27 July 2021
- Published by Springer Nature in Clinical Rheumatology
- Vol. 40 (12) , 4861-4867
Open AccessAbatacept in rheumatoid arthritis-associated interstitial lung disease: short-term outcomes and predictors of progression
Introduction: Interstitial lung disease in rheumatoid arthritis (RA-ILD) is an extra-articular involvement that impairs the prognosis and for which there is still no well-coded treatment. The aim of this study was to evaluate abatacept (ABA) effectiveness and safety in patients with RA-ILD. Methods: RA-ILD patients who started ABA treatment were consecutively enrolled. Chest high-resolution computed tomography (HRCT), clinical, laboratory and respiratory function variables were collected at baseline and after 18 months of ABA treatment. HRCT abnormalities were evaluated using a computer-aided method (CaM). ABA response was established based on the change in the percentage of fibrosis evaluated at HRCT-CaM, dividing patients into “worsened” (progression ≥ 15%), “improved” (reduction ≥ 15%), and “stable” (changes within the 15% range). The multivariate regression model was used to assess the associations between RA characteristics and ABA response. Results: Forty-four patients (81% women, mean age 59.1 ± 8.0, mean disease duration of 7.5 ± 3.1 years) were studied. Five patients (11.4%) showed RA-ILD progression, 32 patients (72.6%) were considered stable, and 7 patients (16.0%) showed an RA-ILD improvement. The proportion of current smokers was significantly different between “worsened” patients, respect to those defined as "improved/stable” (p = 0.01). Current smoking habit (p = 0.005) and concomitant methotrexate treatment (p = 0.0078) were the two variables related to RA-ILD progression in multivariate regression analysis. Conclusion: Treatment with ABA is associated with a RA-ILD stability or improvement in the 88.6% of patients. Current smoking habit and concomitant treatment with methotrexate are the modifiable factors associated with RA-ILD worsening. Key Points• Abatacept plays a favourable role in the control of RA-ILD, with a significant worsening in only 11.4% of patients during a 18-month follow-up period.• The predictive variables related to RA-ILD progression during abatacept therapy are the concomitant treatment with methotrexate and current smoking habit.
- Open Access
- 19 March 2021
- Published by Wolters Kluwer Health in Medicine
- Vol. 100 (11) , e24833
Mild cognitive impairment in psoriatic arthritis
To assess the prevalence and factors associated with mild cognitive impairment (MCI) in patients suffering from psoriatic arthritis (PsA). A cross-sectional evaluation was conducted in consecutive PsA patients. Sociodemographic data and the clinimetric variables related to PsA and psoriasis were collected for each patient. MCI was assessed through the Montreal Cognitive Assessment (MoCA). The cognitive performance of PsA patients was compared to healthy subjects using one-way analysis of variance (ANOVA). The correlations among variables were studied by the Spearman rank correlation coefficient. A multivariate logistic regression analysis was carried out to establish the predictors of MCI. The study involved 96 PsA patients and 48 healthy subjects. MCI (defined as a MoCA score < 26/30) was detected in 47 (48.9%) PsA patients. Compared to healthy subjects, the MoCA score resulted significantly lower in PsA patients (P = .015). The main differences involved the denomination and language domains. MoCA was negatively correlated with age (r = −0.354; P < .0001), HAQ-DI (r = −0.227; P = .026), and fatigue (r = −0.222; P = .029), and positively correlated with psoriasis duration (r = 0.316; P = .001) and DLQI (r = 0.226; P = .008). The multivariate logistic regression analysis revealed the duration of psoriasis (P = .0005), age (P = .0038), PASI (P = .0050), and HAQ-DI (P = .0193) as predictors of the MoCA score. MCI is present in a significant proportion of PsA patients, and is mainly determined by age, cutaneous variables, and disability.
- 19 March 2021
- Published by Wolters Kluwer Health in Medicine
- Vol. 100 (11) , e24833
Open AccessMild cognitive impairment in psoriatic arthritis
To assess the prevalence and factors associated with mild cognitive impairment (MCI) in patients suffering from psoriatic arthritis (PsA). A cross-sectional evaluation was conducted in consecutive PsA patients. Sociodemographic data and the clinimetric variables related to PsA and psoriasis were collected for each patient. MCI was assessed through the Montreal Cognitive Assessment (MoCA). The cognitive performance of PsA patients was compared to healthy subjects using one-way analysis of variance (ANOVA). The correlations among variables were studied by the Spearman rank correlation coefficient. A multivariate logistic regression analysis was carried out to establish the predictors of MCI. The study involved 96 PsA patients and 48 healthy subjects. MCI (defined as a MoCA score < 26/30) was detected in 47 (48.9%) PsA patients. Compared to healthy subjects, the MoCA score resulted significantly lower in PsA patients (P = .015). The main differences involved the denomination and language domains. MoCA was negatively correlated with age (r = −0.354; P < .0001), HAQ-DI (r = −0.227; P = .026), and fatigue (r = −0.222; P = .029), and positively correlated with psoriasis duration (r = 0.316; P = .001) and DLQI (r = 0.226; P = .008). The multivariate logistic regression analysis revealed the duration of psoriasis (P = .0005), age (P = .0038), PASI (P = .0050), and HAQ-DI (P = .0193) as predictors of the MoCA score. MCI is present in a significant proportion of PsA patients, and is mainly determined by age, cutaneous variables, and disability.
- Open Access
- 16 October 2020
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (42) , e22433
The role of a chest computed tomography severity score in coronavirus disease 2019 pneumonia
The chest computed tomography (CT) characteristics of coronavirus disease 2019 (COVID-19) are important for diagnostic and prognostic purposes. The aim of this study was to investigate chest CT findings in COVID-19 patients in order to determine the optimal cut-off value of a CT severity score that can be considered a potential prognostic indicator of a severe/critical outcome. The CT findings were evaluated by means of a severity score that included the extent (0–4 grading scale) and nature (0–4 grading scale) of CT abnormalities. The images were evaluated at 3 levels bilaterally. A receiver operating characteristics (ROC) curve was used to identify the optimal score (Youden's index) predicting severe/critical COVID-19. The study involved 165 COVID-19 patients (131 men [79.4%] and 34 women [20.6%] with a mean age of 61.5 ± 12.5 years), of whom 30 (18.2%) had severe/critical disease and 135 (81.8%) mild/typical disease. The most frequent CT finding was bilateral predominantly subpleural and basilar airspace changes, with more extensive ground-glass opacities than consolidation. CT findings of consolidation, a crazy-paving pattern, linear opacities, air bronchogram, and extrapulmonary lesions correlated with severe/critical COVID-19. The mean CT severity score was 63.95 in the severe/critical group, and 35.62 in the mild/typical group (P < .001). ROC curve analysis showed that a CT severity score of 38 predicted the development of severe/critical symptoms. A CT severity score can help the risk stratification of COVID-19 patients.
- 16 October 2020
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (42) , e22433
Open AccessThe role of a chest computed tomography severity score in coronavirus disease 2019 pneumonia
The chest computed tomography (CT) characteristics of coronavirus disease 2019 (COVID-19) are important for diagnostic and prognostic purposes. The aim of this study was to investigate chest CT findings in COVID-19 patients in order to determine the optimal cut-off value of a CT severity score that can be considered a potential prognostic indicator of a severe/critical outcome. The CT findings were evaluated by means of a severity score that included the extent (0–4 grading scale) and nature (0–4 grading scale) of CT abnormalities. The images were evaluated at 3 levels bilaterally. A receiver operating characteristics (ROC) curve was used to identify the optimal score (Youden's index) predicting severe/critical COVID-19. The study involved 165 COVID-19 patients (131 men [79.4%] and 34 women [20.6%] with a mean age of 61.5 ± 12.5 years), of whom 30 (18.2%) had severe/critical disease and 135 (81.8%) mild/typical disease. The most frequent CT finding was bilateral predominantly subpleural and basilar airspace changes, with more extensive ground-glass opacities than consolidation. CT findings of consolidation, a crazy-paving pattern, linear opacities, air bronchogram, and extrapulmonary lesions correlated with severe/critical COVID-19. The mean CT severity score was 63.95 in the severe/critical group, and 35.62 in the mild/typical group (P < .001). ROC curve analysis showed that a CT severity score of 38 predicted the development of severe/critical symptoms. A CT severity score can help the risk stratification of COVID-19 patients.
- Open Access
- 1 September 2019
- Published by Wolters Kluwer Health in Medicine
- Vol. 98 (38) , e17088
High-resolution computed tomography of the lung in patients with rheumatoid arthritis
An international consensus for rheumatoid arthritis (RA) patients at risk of developing interstitial lung disease (ILD) is still lacking. The aims of study were to evaluate: the prevalence of ILD involvement in RA over high-resolution computed tomography (HRCT); the relationships between pulmonary function tests (PFTs), patient-centered measurements, and ILD; and the potential risk factors contributing to RA-ILD patients. Data regarding the clinical characteristics (age, sex, age at onset of RA), laboratory findings (rheumatoid factor [RF] and anti-citrullinated protein antibodies [ACPA]), respiratory functional assessment (forced vital capacity [FVC] and carbon monoxide diffusion capacity [DLCO]), patient-centred measures of dyspnea (PCMD), Health Assessment Questionnaire—Disability Index (HAQ-DI), and HRCT have collected retrospectively. HRCT abnormalities were evaluated using a conventional visual reader-based score (CoVR) and a computer-aided method (CaM). The relationships between the 2 HRCT scores—PFTs and PCMD—were calculated using Pearson correlation. The area under the receiving-operating characteristic (AUC-ROC) curve was calculated to determine the discriminatory performance of measurements between patients with and without ILD. The multivariate regression model was used to evaluate the association force between ILD and RA characteristics. In all, 151 patients (45 males and 106 females, mean age 53.4 ± 7.6 years) were included. ILD had been detected in 29 patients out of 151 (19.2%). Usual interstitial pneumonia was the most common HRCT. RA-ILD patients were older, and older at RA onset (both P < .01), with a higher HAQ-DI ( P < .05) than patients without ILD. ACPA positivity and titer were higher in the RA-ILD group ( P = .02). Extent and severity of ILD, and total CoVR and CaM score closely related to DLCO and PCMD (both P < .0001). A reduced DLCO was the most sensitive test for predicting the presence of ILD on HRCT (AUC-ROC 0.811 ± 0.037). Advanced age ( P < .0001), age at RA onset ( P = .025), ACPA titer ( P = .004), and smoking ( P = .008) were independent explanatory variables of HRCT damage in multivariate analysis. The RA-ILD is associated with age and older age of RA onset, smoking, and ACPA titer. DLCO seems to be the most sensitive parameter to predict ILD on HRCT, followed by PCMD.
- 1 September 2019
- Published by Wolters Kluwer Health in Medicine
- Vol. 98 (38) , e17088
Open AccessHigh-resolution computed tomography of the lung in patients with rheumatoid arthritis
An international consensus for rheumatoid arthritis (RA) patients at risk of developing interstitial lung disease (ILD) is still lacking. The aims of study were to evaluate: the prevalence of ILD involvement in RA over high-resolution computed tomography (HRCT); the relationships between pulmonary function tests (PFTs), patient-centered measurements, and ILD; and the potential risk factors contributing to RA-ILD patients. Data regarding the clinical characteristics (age, sex, age at onset of RA), laboratory findings (rheumatoid factor [RF] and anti-citrullinated protein antibodies [ACPA]), respiratory functional assessment (forced vital capacity [FVC] and carbon monoxide diffusion capacity [DLCO]), patient-centred measures of dyspnea (PCMD), Health Assessment Questionnaire—Disability Index (HAQ-DI), and HRCT have collected retrospectively. HRCT abnormalities were evaluated using a conventional visual reader-based score (CoVR) and a computer-aided method (CaM). The relationships between the 2 HRCT scores—PFTs and PCMD—were calculated using Pearson correlation. The area under the receiving-operating characteristic (AUC-ROC) curve was calculated to determine the discriminatory performance of measurements between patients with and without ILD. The multivariate regression model was used to evaluate the association force between ILD and RA characteristics. In all, 151 patients (45 males and 106 females, mean age 53.4 ± 7.6 years) were included. ILD had been detected in 29 patients out of 151 (19.2%). Usual interstitial pneumonia was the most common HRCT. RA-ILD patients were older, and older at RA onset (both P < .01), with a higher HAQ-DI ( P < .05) than patients without ILD. ACPA positivity and titer were higher in the RA-ILD group ( P = .02). Extent and severity of ILD, and total CoVR and CaM score closely related to DLCO and PCMD (both P < .0001). A reduced DLCO was the most sensitive test for predicting the presence of ILD on HRCT (AUC-ROC 0.811 ± 0.037). Advanced age ( P < .0001), age at RA onset ( P = .025), ACPA titer ( P = .004), and smoking ( P = .008) were independent explanatory variables of HRCT damage in multivariate analysis. The RA-ILD is associated with age and older age of RA onset, smoking, and ACPA titer. DLCO seems to be the most sensitive parameter to predict ILD on HRCT, followed by PCMD.
- 2 July 2019
- Published by Springer Nature in La radiologia medica
- Vol. 124 (10) , 989-999
Ultrasound as a potential tool for the assessment of interstitial lung disease in rheumatic patients. Where are we now?
Lung ultrasound (LUS) achieved an intriguing role in the management of pulmonary involvement in patients affected by connective tissues diseases (CTDs). Few studies have been performed to support its usefulness in the evaluation of the presence and the severity of interstitial lung disease (ILD), relating it to the information obtained with chest high-resolution computed tomography (HRCT). These results open up new fields of research in order to demonstrate the utility of LUS as screening tool to evaluate ILD in CTD. The aim of this review is to provide the “state of the art” of the role of LUS in the management of ILD associated with CTD.
- 2 July 2019
- Published by Springer Nature in La radiologia medica
- Vol. 124 (10) , 989-999
Ultrasound as a potential tool for the assessment of interstitial lung disease in rheumatic patients. Where are we now?
Lung ultrasound (LUS) achieved an intriguing role in the management of pulmonary involvement in patients affected by connective tissues diseases (CTDs). Few studies have been performed to support its usefulness in the evaluation of the presence and the severity of interstitial lung disease (ILD), relating it to the information obtained with chest high-resolution computed tomography (HRCT). These results open up new fields of research in order to demonstrate the utility of LUS as screening tool to evaluate ILD in CTD. The aim of this review is to provide the “state of the art” of the role of LUS in the management of ILD associated with CTD.